| IONIS PHARMACEUTICALS |
| USA |
| Gesundheit |
| US4622221004 / A2ACMZ |
| ISI (Frankfurt) / IONS (NASDAQ) |
| FRA:ISI, ETR:ISI, ISI:GR, NASDAQ:IONS |
| - |
| https://www.ionispharma.c.. |
|
Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address..
>Volltext.. |
| 8588.43 Mio. EUR |
| 8706.2 Mio. EUR |
| 754.11 Mio. EUR |
| -490.19 Mio. EUR |
| -487.44 Mio. EUR |
| -3 EUR |
| 1889.26 Mio. EUR |
| 302.13 Mio. EUR |
| -428.45 Mio. EUR |
| 6.51 |
| -4.58% |
| -117.48% |
| - |
| - |
| - |
| - |
| IONIS |
| 07.09.26 |
|
||||
|